Stockscreener 앱 받기
4.54
0.67%
0.03
전일 마감가:
$4.51
열려 있는:
$4.51
하루 거래량:
22,532
Relative Volume:
0.09
시가총액:
$231.46M
수익:
$84.82M
순이익/손실:
$-21.43M
주가수익비율:
-9.2653
EPS:
-0.49
순현금흐름:
$-27.23M
1주 성능:
-11.50%
1개월 성능:
-1.30%
6개월 성능:
-42.02%
1년 성능:
-61.62%
1일 변동 폭
$4.40
$4.5524
1주일 범위
$4.40
$5.24
52주 변동 폭
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
명칭
Y Mabs Therapeutics Inc
전화
646-885-8505
주소
202 CARNEGIE CENTER, PRINCETON, NY
YMAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
4.54 | 231.46M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.07 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.34 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
559.00 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.84 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-11-18 | 개시 | Oppenheimer | Outperform |
| 2024-08-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-28 | 개시 | Truist | Buy |
| 2023-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-04-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-12-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-10-31 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-10-31 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재개 | Guggenheim | Buy |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-11-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-23 | 재개 | Cowen | Outperform |
| 2021-03-22 | 재개 | JP Morgan | Overweight |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2020-05-01 | 개시 | Janney | Buy |
| 2020-04-29 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-12-24 | 개시 | JP Morgan | Overweight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 개시 | Wedbush | Outperform |
| 2019-04-01 | 개시 | H.C. Wainwright | Buy |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-10-16 | 개시 | BofA/Merrill | Buy |
모두보기
Y Mabs Therapeutics Inc 주식(YMAB)의 최신 뉴스
Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com
Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance
(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE - Defense World
BNP Paribas Financial Markets Has $38,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Jane Street Group LLC - Defense World
YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World
Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB) - The Globe and Mail
How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com
Oppenheimer Adjusts Target Price for Y-mAbs Therapeutics (YMAB) - GuruFocus
Y-mAbs Therapeutics (YMAB) Target Price Lowered by Oppenheimer | YMAB Stock News - GuruFocus
Oppenheimer Adjusts Price Target on Y-mAbs Therapeutics to $15 From $20, Maintains Outperform Rating - marketscreener.com
Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline - TipRanks
Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Transcript : Y-mAbs Therapeutics, Inc.Special Call - marketscreener.com
Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating - marketscreener.com
Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress - TipRanks
Y-mAbs Therapeutics Announces Positive Phase 1 Trial Results for GD2-SADA in Metastatic Solid Tumors and Expands Radiopharmaceutical Pipeline - Nasdaq
Clinical Trial Success: Y-mAbs Breakthrough in Cancer Treatment Shows Promise with Novel Radiopharmaceutical - Stock Titan
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025 - MSN
Y-mAbs Therapeutics, Inc. Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - marketscreener.com
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - The Manila Times
Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting - Nasdaq
Y-mAbs Advanced Cancer Trial Breakthrough: Key Data Coming for Revolutionary GD2-SADA Treatment - Stock Titan
Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles - Investing.com Canada
Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles By Investing.com - Investing.com South Africa
What is HC Wainwright’s Forecast for YMAB FY2026 Earnings? - Defense World
HC Wainwright Issues Pessimistic Estimate for YMAB Earnings - Defense World
Caligan Partners LP Increases Stake in Y-mAbs Therapeutics Inc - GuruFocus
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright - Defense World
What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics - Benzinga
H.C. Wainwright Adjusts Price Target for Y-mAbs Therapeutics (YM - GuruFocus
Price T Rowe Associates Inc. MD Cuts Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
FY2025 EPS Estimates for YMAB Increased by Analyst - Defense World
Formulation Is Key For Y-mAbs' Self-Assembling Antibody - Bioprocess Online
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Oppenheimer Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Q2 EPS Estimates for Y-mAbs Therapeutics Cut by Wedbush - Defense World
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates - MSN
Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook - TipRanks
Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Y-mAbs Therapeutics (YMAB) Maintains "Outperform" Rating, PT Low - GuruFocus
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Y Mabs Therapeutics Inc (YMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Y Mabs Therapeutics Inc 주식 (YMAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rossi Michael J | PRESIDENT & CEO |
Mar 07 '25 |
Sale |
5.20 |
3,917 |
20,368 |
137,083 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Mar 07 '25 |
Sale |
5.23 |
10,810 |
56,536 |
202,721 |
1.21%
2.91%
자본화:
|
볼륨(24시간):